^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Clear Cell Renal Cell Carcinoma
    Drug:Bavencio (avelumab) (PD-L1 inhibitor) +
    axitinib (VEGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    First-line therapy for clear cell histology: Other recommended regimens…Axitinib + Avelumab